The Pilot Project Program is an important part of the Duke SPORE in Breast Cancer. Combined with the Planning Grant in Breast Cancer (an NCI R21, or 'baby SPORE'), we have provided $750,000 to a diverse group of investigators at Duke during the past three years. This funding was critical to building a vital and productive breast cancer research program and bringing together the expertise and resources to successfully garner a SPORE grant. The SPORE provided three pilot proposal substantial support for two years. These grants were reviewed competitively during our first submission and each emphasized development of novel therapeutics. In the third and final year of our SPORE, we chose three projects that emphasized susceptibility genetics. These proposal were selected from a field of 25 submissions answering a Cancer Center-wide RFA. Each submission was limited to two pages and an abbreviated budget salary support and supplies (no equipment or travel). Selection was done by a subcommittee appointed by the Direction and approved by the Executive Committee. During the fourth and fifth years covered by this supplement, we propose to allocated $40,000 each year to pilot projects and to recruit and select two or three by the same mechanism outlined for the current year. The reduction of support for this Program is justified by: 1.) A competitive renewal will be submitted during the fourth year, 2.) The SPORE will concentrate on finishing its six major projects supported by a reduced overall budget, and 3.) We have created a diverse based of research by granting an unprecedented number of small and moderate-size grants during the past three years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA068438-05
Application #
6203344
Study Section
Project Start
1999-09-01
Project End
2003-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Osada, Takuya; Hartman, Zachary C; Wei, Junping et al. (2018) Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Res 20:90
Goncalves, Rodrigo; DeSchryver, Katherine; Ma, Cynthia et al. (2017) Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Res Treat 165:355-364
Mertins, Philipp; Yang, Feng; Liu, Tao et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13:1690-704
Li, Shunqiang; Shen, Dong; Shao, Jieya et al. (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4:1116-30
Cao, Yiting; Eble, Joseph M; Moon, Ejung et al. (2013) Tumor cells upregulate normoxic HIF-1? in response to doxorubicin. Cancer Res 73:6230-42
Ellis, Matthew J; Ding, Li; Shen, Dong et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-60
D'Amato, Nicholas C; Ostrander, Julie H; Bowie, Michelle L et al. (2012) Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One 7:e45684
Aird, Katherine M; Allensworth, Jennifer L; Batinic-Haberle, Ines et al. (2012) ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 132:109-19
Il'yasova, Dora; Kennedy, Kelly; Spasojevic, Ivan et al. (2011) Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat 125:583-9
Ye, Xiaodong; Fels, Diane; Tovmasyan, Artak et al. (2011) Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radic Res 45:1289-306

Showing the most recent 10 out of 103 publications